News Analysis India

Tag: Sadananda Gowda

  • Govt allocates additional 1.7 lakh vials of Amphotericin-B to states, UTs

    By PTI
    NEW DELHI: The government has allocated an additional 1.7 lakh vials of Amphotericin-B drug, used to treat black fungus infection, to states and union territories, Union Minister Sadananda Gowda said on Wednesday.

    “Ensuring adequate availability and smooth supply of #Amphotericin-B across the country, additional 1,70,000 vials of the drug have been allocated to all the States/UTs & Central Institutions today,” the chemicals and fertilisers minister tweeted.

    Gowda added that an additional 15,520 vials of the critical drug have been allocated to Karnataka.

    “So far, a total of 40,470 vials of the drug have been allocated to the state including today’s allocation for timely treatment of patients,” he said.

    Amphotericin-B is used to treat Mucormycosis, also known as black fungus, which damages the nose, eyes, sinuses, and sometimes even the brain.

    Mucormycosis can be life-threatening in diabetic or severely immuno-compromised individuals such as cancer patients or people with HIV/AIDS.

    The doctors in India are documenting an alarming number of cases of Mucormycosis among patients with COVID-19 and those who have recently recovered.

    They believe that Mucormycosis may be triggered by the use of steroids, a life-saving treatment for severe and critically ill COVID-19 patients.

  • Additional 30,100 vials of Amphotericin-B allocated to states, UTs: Sadananda Gowda

    By PTI
    BENGALURU: An additional 30,100 vials of Amphotericin-B was allocated to all the states and Union Territories by the Centre on Monday to combat the black fungus infection, Union Minister for Chemicals and Fertilisers D V Sadananda Gowda said.

    “Additional 30,100 vials of #Amphotericin-B have been allocated to all the States/UTs and Central Institutions today,” the Minister tweeted on Monday. He said an additional 1,930 vials of Amphotericin-B has been allocated to Karnataka.

    With this, the state has so far received 12,710 vials. According to the state health department, 1,250 people have been infected by black fungus so far in Karnataka, of whom 39 have died and 18 have recovered.

    The other 1,193 infected people are undergoing treatment, it said in a statement.

  • Govt allocated additional 19,420 vials of Amphotericin-B to states, UTs: Union Minister Gowda

    By PTI

    NEW DELHI: The government has allocated additional 19,420 vials of Amphotericin-B to various states, Union Territories (UTs) and Central Institutions on May 24, Union Minister Sadananda Gowda said on Tuesday.

    Amphotericin-B is used to treat Mucormycosis, also known as black fungus, which damages nose, eyes, sinuses, and sometimes even the brain.

    “Additional 19,420 vials of #Amphotericin- B have been allocated to all States/UTs and Central Institutions,” Gowda, who is Union Minister of Chemicals and Fertilisers, tweeted.

    In the latest allocation of 19,420 vials, Gujarat has received 4,640 vials, while Maharashtra has got 4,060 vials.

    Other noteworthy recipients were Andhra Pradesh (1,840 vials), followed by Madhya Pradesh (1,470), Rajasthan (1,430), Uttar Pradesh (1,260) and Karnataka (1,030).

    The government had earlier on May 21, allocated 23,680 vials of Amphotericin-B to various states and Union Territories.

    Mucormycosis is a very rare infection which is caused by exposure to mucor mould which is commonly found in soil, plants, manure, and decaying fruits and vegetables.

    It affects the sinuses, the brain and the lungs and can be life-threatening in diabetic or severely immuno-compromised individuals such as cancer patients or people with HIV/AIDS.

    The doctors in India are documenting an alarming number of cases of Mucormycosis among patients with COVID-19 and those who have recently recovered.

    They believe that Mucormycosis may be triggered by the use of steroids, a life-saving treatment for severe and critically ill COVID-19 patients.

  • Black fungus treatment: Centre allocates additional 23,680 vials of Amphotericin-B to states/UTs

    By PTI
    NEW DELHI: With cases of mucormycosis or black fungus increasing, the government has allocated 23,680 additional vials of Amphotericin-B to various states and union territories (UTs), Union Minister Sadananda Gowda said on Saturday.

    The allocation has been made based on the total number of patients which is around 8,848 across the country, he noted. “After a detailed review of rising no.of cases of #Mucormycosis in various states, a total of 23,680 additional vials of #Amphotericin- B have been allocated to all States/UTs today,” Gowda, who is Minister of Chemicals and Fertilisers, tweeted.

    After a detailed review of rising no. of cases of #Mucormycosis in various states, a total of 23680 additional vials of #Amphotericin- B have been allocated to all States/UTs today.The Allocation has been made based on total no. of patients which is approx. 8848 across country. pic.twitter.com/JPsdEHuz0W
    — Sadananda Gowda (@DVSadanandGowda) May 22, 2021

    He noted that states like Andhra Pradesh, Gujarat, Haryana, Karnataka, Madhya Pradesh, Maharashtra, Rajasthan and telangana have been allotted 75 per cent of the additional vials. Mucormycosis, also known as black fungus, damages the nose, eyes, sinuses, and sometimes even the brain.

    ALSO READ| Over 5 lakh vials of black fungus drug amphotericinB to be imported in May-June: Centre

    It is a very rare infection which is caused by exposure to mucor mould which is commonly found in soil, plants, manure, and decaying fruits and vegetables. It affects the sinuses, the brain and the lungs and can be life-threatening in diabetic or severely immuno-compromised individuals such as cancer patients or people with HIV/AIDS.

    The doctors in India are documenting an alarming number of cases of mucormycosis among patients with COVID-19 and those who have recently recovered. They believe that mucormycosis may be triggered by the use of steroids, a life-saving treatment for severe and critically ill COVID-19 patients.